HeartBeam Establishes Scientific Advisory Board and Appoints C. Michael Gibson, MD as Chairman
January 27 2022 - 9:42AM
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage
digital healthcare company with a proprietary ECG telemedicine
technology to bring new capabilities to cardiovascular disease,
today announced the establishment of a Scientific Advisory Board
(SAB) to provide scientific guidance and insight to the Company’s
medical studies, research and product pipelines. In conjunction,
world-renowned cardiologist C. Michael Gibson, MS, MD, was
appointed as Chairman of the new SAB.
C. Michael Gibson, MS, MD is an interventional cardiologist,
cardiovascular researcher, and educator who pioneered understanding
of the “open artery hypothesis” as well as understanding of the
importance of restoring flow downstream in the capillary bed in the
“open microvasculature hypothesis” in a heart attack. Dr. Gibson
has been a leading investigator in trials of thrombolytic agents,
glycoprotein 2b3a inhibitor agents, thienopyridines, factor Xa
inhibitors, lipid-lowering agents and new devices. Dr. Gibson was
named one of the world’s most widely published and cited scientists
of past decade in 2018 - 2021 by Thomson Reuters.
Dr. Gibson founded and led his own Academic Research
Organization (PERFUSE) for 30 years and has been the principal
investigator of or led core services for over 120 clinical trials,
the results of which have been published in leading journals. Under
Dr. Gibson’s direction, PERFUSE created the master database that
unified data from over many years of TIMI studies (TIMI 1-50) in
nearly 100,000 patients and coordinated data analyses for the TIMI
study group and functioned as the TIMI Data Coordinating Center. He
has led phase 1-4 clinical trials, and cardiology megatrials of
over 15,000 patients which eventuate in international approval of
drugs like prasugrel, rivaroxaban, and betrixaban.
Dr. Gibson also founded www.wikidoc.org and www.wikipatient.org,
widely viewed open-source textbooks of medicine. He also founded
www.clinicaltrialresults.org and has conducted >2,000 TV/video
interviews. He has 440K followers on Twitter with millions of
impressions at major meetings.
“I am privileged to be appointed Chair of the Scientific
Advisory Board and look forward to bringing together a group of
highly accomplished and experienced individuals to support
HeartBeam’s technology platform,” said Dr. Gibson. “We intend to
select additional SAB members who will bring expertise that will
help drive the company to success in the use of its proprietary ECG
telemedicine technology to help diagnose heart attacks in patients
outside of a medical institution.”
“On behalf of our Board of Directors and management team, we
welcome Dr. Gibson to the newly established SAB, bringing over
three decades of leadership in cardiology as a researcher and one
of world’s leading cardiologists,” said Branislav Vajdic, PhD,
Chief Executive Officer and Founder of HeartBeam. “His scientific
perspective will provide value in supporting the advancement of our
product development, including our ER solution for more accurate MI
detection and a complete telehealth solution for remote MI
monitoring.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital
healthcare company with proprietary ECG telemedicine technology
that will redefine the way high risk cardiovascular patients are
diagnosed in an ambulatory setting at any time and any place. Its
breakthrough solution employs a reusable, credit card sized, 3D
vector ECG recording device and cloud-based software capable of
assisting a physician in diagnosing a wide range of cardiovascular
disease. HeartBeam is initially focusing on a huge unmet need of
helping diagnose heart attacks in patients outside of a medical
institution. No single lead ECG technology can offer this value to
patients and their physicians. This underserved market is several
times larger than the cardiac arrhythmia detection market based on
the prevalence of patients with coronary artery disease at high
risk of heart attack. For more information visit
www.heartbeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are “forward-looking statements.” While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our recently filed Registration Statement on Form S-1, which can
be found on the SEC’s website at www.sec.gov. We urge you to
consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only
as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in
our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220127005711/en/
Media and Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024